|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| {{drugbox
| | #REDIRECT [[Valsartan#Pharmacology]] |
| | IUPAC_name = 3-methyl-2- [pentanoyl-[ [4-[2-(2''H''-tetrazol-5-yl) phenyl] phenyl] methyl]amino] -butanoic acid
| |
| | image = Valsartan_svg.png
| |
| | CAS_number = 137862-53-4
| |
| | ATC_prefix = C09
| |
| | ATC_suffix = CA03
| |
| | ATC_supplemental =
| |
| | PubChem = 60846
| |
| | DrugBank = APRD00133
| |
| | C = 24 | H = 29 | N = 5 | O = 3
| |
| | molecular_weight = 435.519 g/mol
| |
| | bioavailability =
| |
| | protein_bound = 95%
| |
| | metabolism =
| |
| | elimination_half-life = 6 hours
| |
| | pregnancy_category = D
| |
| | legal_status = Rx-only
| |
| | routes_of_administration = oral
| |
| }}
| |
| {{CMG}}
| |
| | |
| {{Editor Join}}
| |
| | |
| ==[[Valsartan (patient information)|For patient information, click here]]==
| |
| | |
| '''Valsartan''' is an [[angiotensin II receptor antagonist]], acting on the [[angiotensin receptor|AT<sub>1</sub>]] subtype. In the U.S., valsartan is indicated for treatment of [[hypertension|high blood pressure]], of [[congestive heart failure]] (CHF), and post-[[myocardial infarction]] (MI). It is marketed by [[Novartis]] under the trade name '''Diovan®'''. In 2005, Diovan® was prescribed more than 12 million times in the [[United States]]. A study released by the [[Journal of Clinical Investigation]] in 2007 found some efficacy in the use of Valsartan in the treatment and prevention of [[Alzheimer's disease]] although such use is considered to be highly experimental.<ref>"Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease." http://content.the-jci.org/articles/view/31547 . 2007.</ref>
| |
| | |
| ==Administration==
| |
| Oral tablets, containing 40 mg (scored), 80 mg, 160 mg or 320 mg of valsartan. Usual dosage ranges from 40–320 mg daily.
| |
| | |
| In some markets available as a Hard Gelatin Capsule, containing 40mg, 80mg, or 160mg of valsartan.
| |
| | |
| '''Diovan HCT®''' contains a combination of Valsartan and [[hydrochlorothiazide]] but, unlike Diovan®, is only indicated for hypertension, not for CHF or post-MI.
| |
| | |
| ==Side effects==
| |
| Most commonly, [[headache]] and [[dizziness]].
| |
| | |
| ==References==
| |
| <div style="font-size:85%">
| |
| <references/>
| |
| </div>
| |
| | |
| ==External links==
| |
| *{{PubMed|Valsartan}}
| |
| *[http://www.diovan.com Official Diovan Site]
| |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| | |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Novartis]]
| |
| [[Category:Drugs]]
| |
| | |
| [[de:Valsartan]]
| |
| [[es:Valsartán]]
| |
| [[hu:Valsartan]]
| |
| [[pt:Valsartan]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |